IMDX

Insight Molecular Diagnostics
$4.70
−$0.04 (−0.84%)Jul 27, 2026
1.9PoorMoatMint rating

MoatMint rates Insight Molecular Diagnostics (IMDX) 1.9 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 2.1 out of 10.

Key metrics

The numbers that frame IMDX today
Market cap
$151.76M
P/E (TTM)
-3.2
EV / FCF
-4.6
Gross margin
51.3%
EV / Sales
64.6
ROIC
-981.2%
Div yield
0%
52wk Low
$2.33
52wk High
$8.51

IMDX stock rating

How IMDX scores on quality, value, growth, momentum and financial health
1.9out of 10
Low overallNeutral business, expensive priceTop 81% of ~5,000 US stocks
QualityFair2.1/10
GrowthPoor0.3/10
MomentumGreat8.1/10
ValuePoor1.2/10
Financial HealthPoor1.3/10

Growth

Revenue and earnings trend for IMDX
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about IMDX
Is Insight Molecular Diagnostics a good buy?
Hold. Insight Molecular Diagnostics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Insight Molecular Diagnostics is selling at a very high price.
What is the market capitalization of IMDX?
Insight Molecular Diagnostics's market capitalization is $151.76M.
What is the P/E ratio for IMDX stock?
Insight Molecular Diagnostics's current P/E ratio is -3.2.
What is the 52-week high for IMDX stock?
The 52-week high for Insight Molecular Diagnostics is $8.51. The current close of $4.70 is 44.8% below that high.
What is the 52-week low for IMDX stock?
The 52-week low for Insight Molecular Diagnostics is $2.33. The current close of $4.70 is 101.7% above that low.
Does IMDX stock pay dividends?
Insight Molecular Diagnostics does not currently show a dividend per share in the company data.